Sign in →

Test Code SMCP Inherited Skeletal Muscle Channelopathy Gene Panel, Varies


Ordering Guidance


Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

 

Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH/ Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Specimen Required


Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated

Additional Information: To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.


Forms

1. New York Clients-Informed consent is required.

Document on the request form or electronic order that a copy is on file.

The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Molecular Genetics: Neurology Patient Information

3. If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.

Useful For

Establishing a molecular diagnosis for patients with a skeletal muscle channelopathy

 

Identifying variants within genes known to be associated with a skeletal muscle channelopathy allowing for predictive testing of at-risk family members

Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 5 genes associated with skeletal muscle channelopathies: ATP1A2, CACNA1S, CLCN1, KCNJ2, SCN4A. For more information see Method Description and Targeted Genes and Methodology Details for Inherited Skeletal Muscle Channelopathy Gene Panel.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for skeletal muscle channelopathies.

Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

Reporting Name

Muscle Channelopathy Gene Panel

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

Skeletal muscle channelopathies are neuromuscular disorders with onset predominantly in childhood and are characterized by episodic symptoms of either myotonia or paralysis. Skeletal muscle channelopathies can be divided into nondystrophic myopathies and periodic paralyses. The nondystrophic myotonias include myotonia congenita, paramyotonia congenita, and sodium channel myotonia and are characterized by muscle stiffness generated by voluntary movement. Other features include transient or prolonged weakness, pain associated with myotonia, and fatigue. The periodic paralyses include hyperkalemic periodic paralysis, hypokalemic periodic paralysis, and Andersen-Tawil syndrome and are characterized by episodic attacks of weakness, often triggered by diet or rest after exercise.

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Day(s) Performed

Varies

Report Available

14 to 21 days

Specimen Retention Time

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81403

81406 x 3

81479

81479 (if appropriate for government payers)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SMCP Muscle Channelopathy Gene Panel 102119-5

 

Result ID Test Result Name Result LOINC Value
617728 Test Description 62364-5
617729 Specimen 31208-2
617730 Source 31208-2
617731 Result Summary 50397-9
617732 Result 82939-0
617733 Interpretation 69047-9
618192 Additional Results 82939-0
617734 Resources 99622-3
617735 Additional Information 48767-8
617736 Method 85069-3
617737 Genes Analyzed 48018-6
617738 Disclaimer 62364-5
617739 Released By 18771-6

Testing Algorithm

For more information see Neuromuscular Myopathy Testing Algorithm